[1] |
Chakaya J, Khan M, Ntoumi F, et al. Global Tuberculosis Report 2020-Reflections on the Global TB burden, treatment and prevention efforts. Int J Infect Dis, 2021, 113(Suppl 1): S7-S12. doi:10.1016/j.ijid.2021.02.107.
doi: 10.1016/j.ijid.2021.02.107
|
[2] |
徐彩红, 赵雁林. 从《2020年全球结核病报告》看我国结核病防治工作. 中华传染病杂志, 2021, 39(7): 392-397. doi:10.3760/cma.j.cn311365-20210406-00117.
doi: 10.3760/cma.j.cn311365-20210406-00117
|
[3] |
刘一典. 复治肺结核病诊断和治疗专家共识. 中国防痨杂志, 2021, 43(12): 1226-1238. doi:10.3969/j.issn.1000-6621.2021.12.002.
doi: 10.3969/j.issn.1000-6621.2021.12.002
|
[4] |
中华医学会结核病学分会. 中国耐多药和利福平耐药结核病治疗专家共识(2019年版). 中华结核和呼吸杂志, 2019, 42(10): 733-749. doi:10.3760/cma.j.issn.1001-0939.2019.10.006.
doi: 10.3760/cma.j.issn.1001-0939.2019.10.006
|
[5] |
陈明. 结核患者血清尿酸与吡嗪酰胺血药浓度关系研究. 中国药物应用与监测, 2018, 15(5): 274-276. doi:10.3969/j.issn.1672-8157.2018.05.004.
doi: 10.3969/j.issn.1672-8157.2018.05.004
|
[6] |
蒲强红, 李佳萌, 李凡敏, 等. 结核病化疗药物吡嗪酰胺致高尿酸血症的危险因素研究. 中华全科医学, 2021, 19(12): 2058-2060, 2152. doi:10.16766/j.cnki.issn.1674-4152.002236.
doi: 10.16766/j.cnki.issn.1674-4152.002236
|
[7] |
Ichida K, Hosoyamada M, Kimura H, et al. Urate transport via human PAH transporter hOAT1 and its gene structure. Kidney Int, 2003, 63(1): 143-155. doi:10.1046/j.1523-1755.2003.00710.x.
doi: 10.1046/j.1523-1755.2003.00710.x
pmid: 12472777
|
[8] |
Enomoto A, Kimura H, Chairoungdua A, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature, 2002, 417(6887): 447-452. doi:10.1038/nature742.
doi: 10.1038/nature742
URL
|
[9] |
Hediger MA, Johnson RJ, Miyazaki H, et al. Molecular physiology of urate transport. Physiology (Bethesda), 2005, 20: 125-133. doi:10.1152/physiol.00039.2004.
doi: 10.1152/physiol.00039.2004
|
[10] |
Enomoto A, Kimura H, Chairoungdua A, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature, 2002, 417(6887): 447-452. doi:10.1038/nature742.
doi: 10.1038/nature742
URL
|
[11] |
彭惠, 申恩瑞, 马世武. 吡嗪酰胺诱导的高尿酸血症. 传染病信息, 2018, 31(4): 376-380. doi:10.3969/j.issn.1007-8134.2018.04.019.
doi: 10.3969/j.issn.1007-8134.2018.04.019
|
[12] |
Ha YJ, Chung SW, Lee JH, et al. Clinical features and risk factors for gout attacks during anti-tuberculosis treatment: A case-control study in South Korea. Int J Rheum Dis, 2019, 22(10): 1905-1911. doi:10.1111/1756-185X.13697.
doi: 10.1111/1756-185X.13697
URL
|
[13] |
袁进, 梁虹艺, 石磊. 吡嗪酰胺抗结核化疗致高尿酸血症流行病学调查. 药物流行病学杂志, 2012, 21(2): 78-80. doi:10.19960/j.cnki.issn1005-0698.2012.02.009.
doi: 10.19960/j.cnki.issn1005-0698.2012.02.009
|
[14] |
So A, Thorens B. Uric acid transport and disease. J Clin Invest, 2010, 120(6): 1791-1799. doi:10.1172/JCI42344.
doi: 10.1172/JCI42344
pmid: 20516647
|
[15] |
Tin A, Woodward OM, Kao WH, et al. Genome-wide association study for serum urate concentrations and gout among African Americans identifies genomic risk loci and a novel URAT 1 loss-of-function allele. Hum Mol Genet, 2011, 20(20): 4056-4068. doi:10.1093/hmg/ddr307.
doi: 10.1093/hmg/ddr307
URL
|
[16] |
Cho SK, Kim S, Chung JY, et al. Discovery of URAT 1 SNPs and association between serum uric acid levels and URAT1. BMJ Open, 2015, 5(11): e009360. doi:10.1136/bmjopen-2015-009360.
doi: 10.1136/bmjopen-2015-009360
|
[17] |
Li C, Yu Q, Han L, et al. The hURAT1 rs559946 polymorphism and the incidence of gout in Han Chinese men. Scand J Rheumatol, 2014, 43(1): 35-42. doi:10.3109/03009742.2013.808375.
doi: 10.3109/03009742.2013.808375
pmid: 23981340
|
[18] |
张小珍. SLC2A9、SLC22A12、SLC17A1和GCKR基因多态性分子诊断技术的建立与应用. 兰州:兰州大学, 2018.
|
[19] |
Zou Y, Du J, Zhu Y, et al. Associations between the SLC22A12 gene and gout susceptibility:a meta-analysis. Clin Exp Rheumatol, 2018, 36(3): 442-447.
|
[20] |
Tu HP, Chung CM, Min-Shan Ko A, et al. Additive compo-site ABCG2, SLC2A9 and SLC22A12 scores of high-risk alleles with alcohol use modulate gout risk. J Hum Genet, 2016, 61(9): 803-810. doi:10.1038/jhg.2016.57.
doi: 10.1038/jhg.2016.57
URL
|